share_log

CVS Health | 4: Statement of changes in beneficial ownership of securities-Officer Mandadi Tilak

CVS Health | 4: Statement of changes in beneficial ownership of securities-Officer Mandadi Tilak

西維斯健康 | 4:持股變動聲明-高管 Mandadi Tilak
美股SEC公告 ·  12/04 06:17

Moomoo AI 已提取核心訊息

On November 30, 2024, Tilak Mandadi, EVP and Chief DDAT Officer of CVS Health, is set to acquire 50,125 shares of Common Stock (RSU) at $59.85 per share. This transaction, classified as a "Grant, award or other acquisition," will increase Mandadi's direct ownership to 99,747 shares.The acquisition, valued at approximately $3 million, represents a significant addition to Mandadi's stake in the company. Following this transaction, Mandadi's total beneficial ownership of CVS Health common stock will amount to 40,414 shares.This stock grant appears to be part of CVS Health's executive compensation program, potentially aligning the interests of senior management with those of shareholders. The transaction is scheduled to be completed on the specified date, subject to any potential changes or company policies regarding executive stock acquisitions.
On November 30, 2024, Tilak Mandadi, EVP and Chief DDAT Officer of CVS Health, is set to acquire 50,125 shares of Common Stock (RSU) at $59.85 per share. This transaction, classified as a "Grant, award or other acquisition," will increase Mandadi's direct ownership to 99,747 shares.The acquisition, valued at approximately $3 million, represents a significant addition to Mandadi's stake in the company. Following this transaction, Mandadi's total beneficial ownership of CVS Health common stock will amount to 40,414 shares.This stock grant appears to be part of CVS Health's executive compensation program, potentially aligning the interests of senior management with those of shareholders. The transaction is scheduled to be completed on the specified date, subject to any potential changes or company policies regarding executive stock acquisitions.
2024年11月30日,西維斯健康的執行副總裁兼首席數字數據和技術官Tilak Mandadi計劃以每股59.85美元的價格收購50,125股普通股(RSU)。這筆交易被歸類爲「授予、獎勵或其他收購」,將使Mandadi直接所有股數增加至99,747股。這項價值約300萬美元的收購,將大幅增加Mandadi在該公司的持股。此次交易完成後,Mandadi對西維斯健康普通股的總受益所有權將達到40,414股。這項股票授予似乎是西維斯健康的高管薪酬計劃的一部分,可能會調動高級管理層與股東的利益。預計該交易將在指定日期完成,視情況可能會有變化,或者受公司有關高管股票收購的政策約束。
2024年11月30日,西維斯健康的執行副總裁兼首席數字數據和技術官Tilak Mandadi計劃以每股59.85美元的價格收購50,125股普通股(RSU)。這筆交易被歸類爲「授予、獎勵或其他收購」,將使Mandadi直接所有股數增加至99,747股。這項價值約300萬美元的收購,將大幅增加Mandadi在該公司的持股。此次交易完成後,Mandadi對西維斯健康普通股的總受益所有權將達到40,414股。這項股票授予似乎是西維斯健康的高管薪酬計劃的一部分,可能會調動高級管理層與股東的利益。預計該交易將在指定日期完成,視情況可能會有變化,或者受公司有關高管股票收購的政策約束。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息